Market Brief

The articles are produced in Chinese only.

Author

劉智健先生 (CK Lau)
助理經理

股票研究投資經驗豐富。利用市場數據、技術走勢及投資氣氛用來分析市況,配合合適的投資工具,為客戶評估風險提供買賣策略。喜歡研究資源類及內需類股票 。
Phone:
2943 7499

錦欣生殖醫療集團有限公司 (1951) ,全年純利3.4億人民幣 增35%

Thursday, June 2, 2022 Views7357

公司概覽

主要在中國及美國提供輔助生殖服務、管理服務及輔助醫療服務。

 

截至2021年12月31日止年度業績

收益約為人民幣1,838.8百萬元,增加 28.9%。

純利約為人民幣353.7百萬元,增加35.8%。

每股基本盈利為人民幣0.14元; 末期股息每股7.38港仙。

 

業務概覽

  • 整體毛利7.71億元上升36.4%,毛利率42%增加2.3個百分點;
  • ARS(輔助生殖服務):營業額11.6億元增加18.6%,佔總營業額63.1%;
  • 管理服務:營業額5.28億元增加40.8%,佔總營業額28.7%;
  • 輔助醫療服務:營業額9456萬元增加31.1%;
  • 按地區劃分:

1﹒大中華區(成都, 深圳及大灣區, 武漢):營業額13.8億元上升31.8%,佔總營業額75%,分部利潤4.1億元增加19.1%;

2﹒美國:營業額4.59億元上升21%,佔總營業額25%,分部利潤8081萬元增長1.5倍;

  • 於2021年12月31日,集團之銀行結餘及現金為8.62億元,而銀行借款為1.64億元。

於報告期內,深圳中山醫院的成功率輕微降低乃主要由於患者的年齡增加及若干 個別病例的情況複雜所致。成功率在很大程度上取決於患者年齡及個別病例的複 雜程度以及其他因素。武漢錦欣醫院的平均成功率下降乃主要由於患者年齡偏 高,以及為在一間新建醫院樹立良好口碑,武漢錦欣醫院有針對性選擇了一些較 複雜的病例

 

展望及未來

儘管ARS行業受COVID-19疫情所影響,但全球ARS市場可望在疫情受控後隨即復甦,並繼續保持其過往多年來的增長趨勢。與ARS於歐洲及美國約30%的市場滲透率相比,ARS於中國的市場滲透率仍然相對較低。此外,集團已着手以成都業務為起點擴大服務範圍,以提供涵蓋備孕、IVF、妊 娠檢查、分娩及產後的全生育生命週期服務,從而透過產業鏈整合為患者提供更好服務及創造價值。通過增加對研發團隊及研究活動的投資來增強我們的研究能力,以維持我們 於輔助生殖技術應用方面的領先地位並提高患者的臨床結果。

 

以短期走勢阻力位為參考, 目標價為HK$ 7.00。

6月1日收市價HK$5.95。

 

*資料來源: 集團公告

 

如有查詢 請聯繫Mr CK LAU

辦公室電話: 29437499

電郵: chikinlau@phillip.com.hk

June 2, 2022

註:本人劉智健為證監會持牌人士。截至本評論文章發表日止,本人及/或其有聯繫者並無持有全部提及之証券的所有相關財務權益。

 

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email : businessenquiry@phillip.com.hk

Enquiry & Support
Branches
The Complaint Procedures
About Us
Phillip Securities Group
Join Us
Phillip Network
Phillip Post
Phillip Channel
Latest Promotion
E-Check
Login
Investor Notes
Free Subscribe
Contact Us